Drug Discovery Strategies for Mycobacterium Tuberculosis

Efforts to discover new therapies against Mycobacterium tuberculosis combine diverse approaches aimed at overcoming the pathogen’s intrinsic defence mechanisms and the emergence of drug resistance. Phenotypic screening of whole‐cell cultures remains a cornerstone, enabling identification of compounds that act across the complex mycobacterial cell envelope and within macrophages. Parallel target‐based campaigns leverage advances in structural biology and chemical genomics to design inhibitors of essential enzymes, transporters and regulatory proteins. Cheminformatic analyses guide library design by mapping physicochemical properties and scaffold diversity, ensuring that novel chemical matter addresses known resistance liabilities. Host‐directed therapies are emerging to enhance immune clearance of bacilli by modulating antimicrobial peptides, phagosome maturation or inflammatory pathways. Repurposing of approved drugs and combinations with existing regimens aim to shorten treatment duration and limit toxicity. Cutting-edge strategies also target non-canonical pathways such as protein quality control, redox buffering and lipid metabolism. Integration of high-throughput screening, mechanistic deconvolution, in vivo efficacy models and pharmacokinetic optimisation underpins a translational pipeline poised to deliver safer, shorter and more effective therapies for tuberculosis.

Research from Nature Portfolio

Recent studies have elucidated how M. tuberculosis utilises its own alanine dehydrogenase to reduce L-alanine levels in infected macrophages, thereby suppressing activation of the NF-κB pathway and downstream antimicrobial peptides. Structural and functional characterisation of the bacterial enzyme revealed its mechanism of hydrolysing host L-alanine and identified small-molecule inhibitors that restore peptide induction. In vivo validation showed that supplementation with L-alanine or administration of a specific alanine dehydrogenase inhibitor markedly enhances bacterial clearance, highlighting a novel immunomodulatory avenue for therapeutic intervention.

Drug Discovery Strategies for Mycobacterium Tuberculosis publication trend

The graph below shows the total number of articles in drug discovery strategies for mycobacterium tuberculosis across all publications each year (not limited to Nature Index journals).

Technical terms

Phenotypic screening: Identification of active compounds based on effects in whole‐cell assays rather than isolated targets.

Mechanism of action (MoA): The specific biochemical interaction through which a compound exerts its effect on a pathogen.

Chemical scaffold: The core molecular framework to which functional groups are attached during drug design.

Proteostasis network: The cellular machinery of chaperones and proteases that ensures proper protein folding and degradation.

Antimicrobial peptide (AMP): Short host-derived molecules that disrupt bacterial membranes and promote pathogen clearance.

Alanine dehydrogenase: A mycobacterial enzyme that hydrolyses L-alanine, implicated in suppression of host immune signalling.

References

1. Mycobacterium tuberculosis suppresses host antimicrobial peptides by dehydrogenating L-alanine. Nature Communications (2024).
2. Unleashing the potential of cheminformatic analysis for Mycobacterium tuberculosis inhibitors: Insights into chemical space and structural diversity. Hybrid Advances (2024).
3. A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis. PLOS ONE (2013).
4. Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening. The Journal of Antibiotics (2019).
5. Targeting the Proteostasis Network for Mycobacterial Drug Discovery. ACS Infectious Diseases (2018).